title: Efficacy and tolerability of a new estradiol delivering matrix patch (Estraderm MX) in postmenopausal women.
abstract: OBJECTIVE
  To examine the efficacy and tolerability of a new matrix patch delivering estradiol (E2 Matrix) at doses of 0.05 and 0.10 mg per day (Estraderm MX 50, 100) in the treatment of moderate to severe postmenopausal symptoms.
  
  
  METHODS
  A total of 254 postmenopausal women were randomized to receive treatment with E2 Matrix 0.10 mg (N = 86), E2 Matrix 0.05 mg (N = 82), or placebo (N = 86) in a double-blind, double-dummy fashion for a period of 12 weeks continuously. Patches were applied twice weekly to the buttocks with each patient wearing two patches at all times. The primary efficacy criterion was the difference from baseline of the mean number of moderate to severe hot flushes per 24 h during the last 2 weeks of treatment. Other efficacy variables included reduction in hot flushes at 4 and 8 weeks, reduction in daytime flushing and night sweats, and Kupperman Index at 4, 8, and 12 weeks.
  
  
  RESULTS
  E2 Matrix 0.10 and 0.05 mg were both significantly superior to placebo in reducing hot flushes per 24 h after 4, 8, and 12 weeks of treatment (P < 0.001). Also, for all other efficacy parameters studied, both dosage strengths of E2 Matrix were statistically significantly superior to placebo at all time points (P < 0.001). Local tolerability was good in both groups. A slight increase in estrogen related adverse effects (breast tenderness, leukorrhoea) was seen with the 0.10 mg patch. Adhesion of patches and compliance were good. Overall systemic tolerability was good in both treated groups. However, a 4.8% overall incidence of endometrial hyperplasia was observed in patients with an intact uterus.
  
  
  CONCLUSIONS
  This new matrix patch offers an effective and well tolerated dosage form for delivery of 0.05 and 0.1 mg estradiol per day. It may be particularly suitable for those women who experience local sensitivity to alcohol-containing systems. In light of the observed hyperplasia after treatment in five patients, estrogen therapy should as yet be supplemented monthly with a progestogen in women with an intact uterus.
authors.affiliation: Department of Obstetrics and Gynaecology, Bosch Medicentrum, Locatie Groot Ziekengasthuis, Hertogenbosch, The Netherlands.
authors.forename: B
authors.initials: B
authors.lastname: de Vrijer
authors.forename: M P
authors.initials: MP
authors.lastname: Snijders
authors.forename: A L
authors.initials: AL
authors.lastname: Troostwijk
authors.forename: S
authors.initials: S
authors.lastname: Thé
authors.forename: R J
authors.initials: RJ
authors.lastname: Iding
authors.forename: S
authors.initials: S
authors.lastname: Friese
authors.forename: D A
authors.initials: DA
authors.lastname: Smit
authors.forename: J M
authors.initials: JM
authors.lastname: Schierbeek
authors.forename: H
authors.initials: H
authors.lastname: Brandts
authors.forename: P J
authors.initials: PJ
authors.lastname: van Kempen
authors.forename: I
authors.initials: I
authors.lastname: van Buuren
authors.forename: G
authors.initials: G
authors.lastname: Monza
mesh_terms: D000279:Administration, Cutaneous; D000328:Adult; D004311:Double-Blind Method; D004958:Estradiol / Q000008:administration & dosage* / Q000494:pharmacology / Q000627:therapeutic use; D005260:Female; D020249:Hormone Replacement Therapy; D019584:Hot Flashes / Q000188:drug therapy*; D006801:Humans; D008875:Middle Aged; D017698:Postmenopause
chemical_list: D004958:Estradiol